{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"USBrandName","name":"Jaypirca"},{"type":"CodeName","name":"LOXO 305"},{"type":"CodeName","name":"LOXO-305"},{"type":"CodeName","name":"LOXO305"},{"type":"CodeName","name":"LY3527727"},{"type":"ChemicalStructureName","name":"5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-((2S)-1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide"},{"type":"Synonym","name":"BTK inhibitor LOXO-305"},{"type":"CASRegistryName","name":"2101700-15-4"}],"definition":{"html":"An orally available, selective, non-covalent Bruton's tyrosine kinase (BTK) inhibitor with potential antineoplastic activity. Upon oral administration, pirtobrutinib selectively and reversibly binds to BTK. This prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, thereby inhibiting the growth of malignant B-cells that overexpress BTK. Reversible binding of LOXO-305 may preserve antitumor activity in the presence of certain acquired resistance mutations, including C481 mutated BTK, and limit toxicity associated with inhibition of other non-BTK kinases. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed or mutated in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B lymphocytes.","text":"An orally available, selective, non-covalent Bruton's tyrosine kinase (BTK) inhibitor with potential antineoplastic activity. Upon oral administration, pirtobrutinib selectively and reversibly binds to BTK. This prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, thereby inhibiting the growth of malignant B-cells that overexpress BTK. Reversible binding of LOXO-305 may preserve antitumor activity in the presence of certain acquired resistance mutations, including C481 mutated BTK, and limit toxicity associated with inhibition of other non-BTK kinases. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed or mutated in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B lymphocytes."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/pirtobrutinib","text":"Pirtobrutinib"},"nciConceptId":"C158617","nciConceptName":"Pirtobrutinib","termId":797383,"name":"pirtobrutinib","firstLetter":"p","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"pirtobrutinib"}],"links":null}